DNA Replication & Repair: Mechanisms and Clinical Relevance
A high-yield medical biochemistry note on semi-conservative DNA replication, leading and lagging strand synthesis, proofreading, major DNA repair pathways, and clinically important repair defects.
Learning outcomes
By the end of this chapter, you should be able to describe the replication fork, explain why DNA synthesis is discontinuous on one strand, distinguish proofreading from repair, match common DNA lesions to repair pathways, and connect pathway failure to clinical patterns such as xeroderma pigmentosum, Lynch syndrome and BRCA-associated cancer.
- Trace initiation, elongation and termination of DNA replication.
- Explain the roles of primers, polymerases, helicase, topoisomerase, clamp and ligase.
- Compare base-excision, nucleotide-excision, mismatch and double-strand-break repair.
- Interpret selected clinical clues without confusing a tumour test with an inherited diagnosis.
1. Core concepts and vocabulary
DNA is a double helix made of two antiparallel nucleotide strands. Complementary base pairing (A with T; G with C) allows each parental strand to guide synthesis of a new strand. Replication is called semi-conservative because each daughter duplex contains one old strand and one newly synthesized strand. The classic Meselson–Stahl experiment demonstrated this model.
In eukaryotic cells, nuclear DNA replication occurs in S phase. Thousands of origins are activated in a regulated sequence so that long chromosomes can be copied efficiently, while origin licensing in the preceding G1 phase helps prevent a DNA segment from being replicated twice in one cycle. Mitochondrial DNA has its own replication machinery and polymerase gamma.
| Term | Meaning | Why it matters |
|---|---|---|
| Origin | Site where replication machinery is assembled and DNA copying begins. | Eukaryotic chromosomes use many origins. |
| Replication fork | Y-shaped region where parental strands separate and new strands are made. | Enzymes work as a coordinated protein complex. |
| Primer | Short RNA–DNA start that provides a free 3′-OH group. | DNA polymerases cannot begin a strand de novo. |
| Okazaki fragment | Short DNA segment made discontinuously on the lagging strand. | Fragments must be processed and joined. |
| Lesion | Chemical or structural abnormality in DNA. | The lesion type helps predict which repair pathway is used. |
2. Initiation: opening DNA and assembling the fork
Origin recognition and licensing proteins mark sites that may be used during the next S phase. In eukaryotes, ORC, CDC6 and CDT1 help load the MCM2–7 helicase complex during licensing; when S phase begins, activation factors form the active CMG helicase (CDC45–MCM–GINS). This separation of licensing from firing is a key safeguard against re-replication.
Helicase separates the parental strands by disrupting base-pair hydrogen bonds. Replication protein A (RPA) coats exposed single-stranded DNA, limiting reannealing and protecting it from damage. Topoisomerases relieve torsional stress ahead of the fork: type I enzymes cut one strand transiently; type II enzymes cut both strands transiently and then reseal them. Primase makes a short RNA primer, and DNA polymerase extends from its 3′ end.
| Component | Main task at the fork | Useful distinction |
|---|---|---|
| Helicase | Unwinds the parental double helix. | Creates the single-stranded templates. |
| RPA / bacterial SSB | Stabilizes exposed single-stranded DNA. | Prevents strands from reannealing. |
| Topoisomerase | Reduces supercoiling and torsional strain. | Different classes are targeted by different drugs. |
| Primase–DNA polymerase α | Creates the initial RNA–DNA primer in eukaryotes. | DNA polymerase needs a pre-existing 3′-OH. |
3. Elongation: why one strand is continuous
The parental strands are antiparallel, but all DNA polymerases extend a new strand only by adding to its 3′-OH; synthesis therefore proceeds 5′→3′. At a moving fork, this chemistry creates a continuous leading strand and a discontinuous lagging strand. Both new strands are still synthesized 5′→3′—the difference is their orientation relative to fork movement.
On the leading template, polymerase can follow the fork continuously. On the lagging template, the enzyme repeatedly starts new fragments as more template is exposed. These Okazaki fragments are later matured: RNA primers are removed, the short gaps are filled with DNA, and DNA ligase I seals remaining nicks by forming phosphodiester bonds. PCNA acts as a sliding clamp that improves polymerase processivity; RFC loads the clamp onto DNA.
| Feature | Leading strand | Lagging strand |
|---|---|---|
| New-strand synthesis | 5′→3′, continuously | 5′→3′, in Okazaki fragments |
| Direction relative to fork | Generally toward the fork | Generally away from the fork |
| Priming | One initial primer for a replicated segment | Repeated primers as the fork advances |
| Finishing step | Continuous product | Primer removal, gap filling and ligation |
Worked direction check: if the template exposed at the fork runs 3′→5′ in the direction the fork travels, its complementary strand can be extended toward the fork. If it runs 5′→3′ in that direction, polymerase must work in short sections away from the fork, producing the lagging strand.
4. Eukaryotic and bacterial replication: shared logic, different proteins
The underlying rules are conserved, but the named enzymes differ. Do not transfer a bacterial protein name to a human replication fork unless the question specifically asks for the comparison.
| Function | Bacterial example (E. coli) | Eukaryotic example |
|---|---|---|
| Origin selection / initiation | DnaA recognizes oriC | ORC and origin-licensing proteins |
| Unwinding | DnaB helicase | CMG helicase complex |
| Primer production | DnaG primase | Pol α–primase |
| Main replicative synthesis | DNA polymerase III holoenzyme | Pol ε (leading) and Pol δ (lagging), in the classical model |
| Primer processing | Pol I and other enzymes | RNase H, FEN1 and polymerase-mediated gap filling |
| Joining fragments | DNA ligase | DNA ligase I |
| Chromosome ends | Circular chromosomes avoid the linear-end problem | Telomeres and telomerase help address end-replication |
These are teaching-level associations rather than a complete inventory of every backup or specialized polymerase. Eukaryotic fork composition can vary with context; bacterial species also differ from E. coli.
5. Replication fidelity: three layers of error control
Base pairing alone is not enough to protect a genome. Fidelity is supported by selective nucleotide insertion, polymerase proofreading and post-replicative mismatch repair. Proofreading is performed during synthesis: a replicative polymerase with 3′→5′ exonuclease activity removes a wrongly paired terminal nucleotide, then resumes extension. This is different from 5′→3′ synthesis.
Mismatch repair (MMR) acts after the polymerase has moved on. It identifies a mispaired base or a small insertion/deletion loop in the newly made strand, removes a short stretch containing the error, resynthesizes it and seals the nick. Repetitive microsatellite sequences are particularly vulnerable to small insertion/deletion errors when MMR is deficient.
| Layer | When it acts | What it corrects |
|---|---|---|
| Polymerase selection | At nucleotide incorporation | Rejects many incorrect nucleotides before they are added. |
| Proofreading | Immediately during elongation | Removes a mismatched nucleotide at the growing 3′ end. |
| Mismatch repair | After an error escapes the fork | Corrects residual mismatches and small loops in the new strand. |
Exam distinction: proofreading is an exonuclease function of the replicating polymerase; MMR is a separate repair pathway. Both reduce mutation but act at different stages.
6. Sources and consequences of DNA damage
DNA damage arises continuously. Endogenous sources include reactive oxygen species, spontaneous hydrolysis (including cytosine deamination and loss of bases), replication-associated mistakes and reactive metabolic by-products. Exogenous sources include ultraviolet light, ionizing radiation, tobacco-related chemicals, some industrial agents and DNA-damaging medicines. A lesion is not automatically a mutation: it becomes a fixed sequence change if it is copied incorrectly or repaired inaccurately before the cell resolves it.
| Damage pattern | Example source | Likely response |
|---|---|---|
| Small altered base / abasic site | Oxidation, deamination, alkylation | Base-excision repair (BER) |
| Bulky helix-distorting lesion | UV photoproducts, bulky chemical adducts | Nucleotide-excision repair (NER) |
| Wrong base pair / short loop after copying | Replication error | Mismatch repair (MMR) |
| Single- or double-strand break | Reactive oxygen species, ionizing radiation, collapsed fork | BER / single-strand-break repair or HR / NHEJ, depending on lesion |
| Interstrand crosslink | Crosslinking chemicals or drugs | Fanconi-anemia pathway and coordinated repair |
Unresolved damage may stall polymerases, collapse a replication fork, trigger a cell-cycle checkpoint, cause cell death or allow a mutation to persist. The outcome depends on lesion type, cell type, cell-cycle stage, repair capacity and whether the cell divides.
7. Base-excision repair and direct reversal
Base-excision repair (BER) corrects small, non-bulky chemical changes that usually do not grossly distort the DNA helix. A lesion-specific DNA glycosylase removes the abnormal base, leaving an abasic (AP) site. AP endonuclease cuts the DNA backbone; repair synthesis replaces the missing nucleotide or short patch, and a DNA ligase seals the strand. Different BER sub-pathways process the resulting DNA ends.
Direct reversal repairs selected chemical modifications without removing a stretch of DNA. Human MGMT transfers certain alkyl groups from guanine to itself; the enzyme is then inactivated, so it is described as a “suicide” repair protein. Photolyase directly reverses UV photoproducts in many organisms, but humans do not use photoreactivation; human UV-lesion repair relies mainly on NER.
| Step in BER | What happens | Memory cue |
|---|---|---|
| Recognition | DNA glycosylase detects a damaged base. | Base is removed first. |
| Incision | AP endonuclease processes the abasic site. | Backbone is cut at the lesion. |
| Repair synthesis | DNA polymerase fills a one- or short multi-nucleotide gap. | Correct sequence is restored using the intact strand. |
| Sealing | DNA ligase closes the nick. | Backbone continuity is restored. |
Clinical link: BER is important for routine oxidative and spontaneous base damage. It is not the classic answer for UV-induced thymine dimers or replication mismatches.
8. Nucleotide-excision repair: removing bulky lesions
Nucleotide-excision repair (NER) removes bulky lesions that distort the DNA helix, including UV-induced cyclobutane pyrimidine dimers and 6–4 photoproducts. Damage can be recognized throughout the genome (global-genome NER) or when it blocks RNA polymerase during transcription (transcription-coupled NER). The pathway opens DNA around the lesion, cuts on both sides, removes a short oligonucleotide, fills the gap by DNA synthesis and ligates the strand.
In humans, NER requires coordinated damage recognition, local unwinding and dual incision by a multi-protein complex. Different genes can be involved, so the phenotype is not explained by a single “UV repair enzyme.” Xeroderma pigmentosum (XP) is the high-yield disorder associated with defective NER; a related XP-variant phenotype may instead involve POLH, which encodes DNA polymerase eta, a translesion polymerase that normally bypasses certain UV lesions more accurately.
A child with marked sun sensitivity, freckling in sun-exposed areas and unusually early skin cancers should prompt clinical consideration of XP and specialist assessment. This pattern is a teaching clue, not enough by itself to establish a genetic diagnosis.
9. Mismatch repair: correcting copying errors after the fork
Mismatch repair recognizes base–base mismatches and small insertion/deletion loops that remain after proofreading. In human cells, MutS-family complexes participate in mismatch recognition (commonly MSH2–MSH6 for base mismatches and small loops; MSH2–MSH3 for larger loops), while MutL-family complexes coordinate incision, excision and resynthesis. The pathway must identify the newly synthesized strand; replication-associated nicks and PCNA help direct this discrimination.
When MMR fails, errors accumulate, especially in repetitive microsatellites, producing microsatellite instability (MSI). Pathogenic germline variants in MLH1, MSH2, MSH6 or PMS2—and certain EPCAM deletions that silence MSH2—can cause Lynch syndrome. However, an MSI-high tumour or abnormal mismatch-repair immunostain does not alone prove the patient has an inherited variant: some tumours acquire MMR deficiency through somatic events. Tumour testing and germline testing answer related but different questions.
| Finding | What it suggests | What it does not prove on its own |
|---|---|---|
| Loss of one or more MMR proteins by tumour IHC | Mismatch-repair deficiency; guides further assessment. | A germline Lynch syndrome variant. |
| MSI-high tumour result | Instability consistent with impaired MMR in the tumour. | That the defect is inherited rather than somatic. |
| Pathogenic germline variant on an appropriate test | Inherited predisposition in the person tested. | The exact cancer outcome or age for an individual. |
When a tumour pattern or family history raises concern, evaluation should follow local referral pathways for genetics, counselling and appropriate testing. A molecular result should be interpreted with the clinical picture and the laboratory report.
10. Double-strand breaks: homologous recombination versus end joining
Double-strand breaks are potentially lethal because both DNA strands are interrupted. Cells can repair them through homologous recombination (HR) or non-homologous end joining (NHEJ), among other context-specific pathways. The choice depends partly on cell-cycle stage and whether a suitable DNA template is available.
| Feature | Homologous recombination (HR) | Non-homologous end joining (NHEJ) |
|---|---|---|
| Template | Uses a homologous sequence, usually the sister chromatid. | Joins broken ends without a homologous template. |
| Typical cell-cycle context | Most available in S/G2 when a sister chromatid exists. | Can operate when no sister chromatid is available, including G1. |
| Sequence outcome | Usually high fidelity when accurately templated. | Can be accurate, but end processing can create small insertions/deletions. |
| Key clinical connection | BRCA1/BRCA2 and related HR genes. | Repair of breaks and programmed antibody-gene rearrangement. |
BRCA1 and BRCA2 are important HR proteins. Loss of HR capacity can create a vulnerability that selected PARP inhibitors exploit in certain cancers (synthetic lethality). This is a tumour biology concept, not a recommendation that every person with a BRCA variant should receive a particular drug; eligibility depends on tumour type, testing, stage, regulatory approval and current specialist guidance.
Interstrand crosslinks covalently join the two DNA strands and prevent them from separating. The Fanconi-anemia pathway coordinates recognition and processing of these lesions with nucleases, translesion synthesis and HR. Inherited Fanconi-anemia syndromes may include bone-marrow failure, congenital features and cancer predisposition; the presentation is variable and requires specialist evaluation.
11. DNA-damage response and replication stress
Repair is coordinated with cell-cycle checkpoints. ATM is classically activated by double-strand breaks, while ATR responds strongly to replication stress and persistent single-stranded DNA at stalled forks. Downstream signalling (including CHK1/CHK2 pathways) can slow cell-cycle progression, stabilize the fork, permit repair and, when damage is severe, contribute to senescence or apoptosis. p53 is one important regulator of cell-cycle arrest and cell fate.
This checkpoint network explains why a damaged cell may pause rather than immediately continue dividing. If the fork collapses or checkpoint signalling is defective, chromosome breaks and rearrangements can accumulate. Ataxia-telangiectasia, caused by biallelic pathogenic variants in ATM, is a classic example linking DNA double-strand-break response failure with neurologic findings, immune problems and cancer susceptibility. Clinical details vary, so this association should prompt specialist assessment rather than stand alone as a diagnosis.
12. Telomeres and the end-replication problem
At the end of a linear chromosome, removal of the last RNA primer on a lagging strand can leave a terminal gap that conventional DNA polymerase cannot fill. Telomeres are repetitive, protein-protected DNA sequences that buffer chromosome ends. Telomerase is a ribonucleoprotein reverse transcriptase that carries an RNA template and extends telomeric DNA, allowing completion of the complementary strand.
Telomerase activity is present in germ-line and selected stem-cell compartments and is reactivated in many cancers, but it is low in most mature somatic cells. Telomere shortening is one contributor to replicative senescence; it is not a simple single-cause explanation of ageing. Some cancers maintain telomeres through alternative lengthening mechanisms rather than telomerase.
13. Pharmacology: how treatments exploit replication and repair
Several anticancer drug classes affect DNA replication or damage handling. These examples show the clinical relevance of the pathways; they are not dosing guidance. The benefit and toxicity depend on indication, combination, organ function, resistance and current local protocols.
Topoisomerase inhibitors
Topoisomerase I inhibitors (for example, irinotecan and topotecan) interfere with resealing of transient single-strand cuts. Topoisomerase II inhibitors (including etoposide and anthracyclines) interfere with the enzyme that manages double-strand passage. Trapped enzyme–DNA intermediates can become damaging when a replication fork collides with them.
Platinum compounds
Platinum drugs form DNA adducts and crosslinks that obstruct replication and transcription. Cells rely on coordinated repair and damage-response pathways to tolerate or resolve these lesions; repair capacity can influence sensitivity and resistance.
PARP inhibitors
PARP enzymes participate in responses to DNA breaks. In selected HR-deficient cancers, PARP inhibition can create synthetic lethality because a backup repair route is also blocked. This principle underlies use of agents such as olaparib in specified cancer settings; it is not universal across all tumours or carriers.
Antimetabolites and nucleoside analogues
Some agents reduce nucleotide availability or are incorporated into DNA/RNA, slowing or disrupting nucleic-acid synthesis. Their effects are not limited to tumour cells, which helps explain toxicity in normal rapidly dividing tissues.
Clinical caution: drug indications change over time and vary by country. For patient-care decisions, check current national guidance, the medicine label and specialist advice.
14. Clinical reasoning: three worked scenarios
Scenario A — severe photosensitivity in a child
A 7-year-old develops freckle-like pigmentation and multiple suspicious lesions on sun-exposed skin after repeated severe sun reactions. The examiner asks which DNA-repair pathway is classically implicated.
Reasoning: UV light creates bulky pyrimidine photoproducts that distort the helix. The classic pathway is nucleotide-excision repair. Xeroderma pigmentosum is the key association; a clinician would arrange specialist dermatology/genetics assessment, not diagnose solely from this vignette.
Scenario B — early colorectal cancer and an abnormal tumour screen
A 42-year-old with colorectal cancer has tumour immunohistochemistry showing loss of an MMR protein; a close relative had endometrial cancer at a young age. The question asks whether the result establishes Lynch syndrome.
Reasoning: the pattern warrants further evaluation for mismatch-repair deficiency and possible Lynch syndrome. Tumour IHC/MSI is a screening or tumour-characterization result; germline testing with appropriate counselling is needed to establish inherited predisposition. Somatic tumour changes can also cause MMR loss.
Scenario C — BRCA-associated tumour and targeted therapy concept
A patient’s tumour is found to carry a pathogenic BRCA1 alteration. A student is asked why a PARP inhibitor may be considered in some cancer settings.
Reasoning: BRCA1/2 help mediate homologous recombination repair. In a tumour with HR deficiency, blocking PARP-dependent repair can create synthetic lethality. The molecular mechanism explains a treatment strategy, but a real treatment decision requires tumour-specific eligibility and current oncology guidance.
| Clue | First pathway to consider | Important qualification |
|---|---|---|
| UV photoproducts / marked photosensitivity | NER | Confirm clinically and genetically as appropriate. |
| MSI-high tumour / MMR protein loss | MMR | Does not by itself distinguish inherited from somatic cause. |
| BRCA1/2 pathogenic alteration | HR | Therapy selection remains tumour- and guideline-specific. |
15. Rapid pathway map and common exam traps
| Question stem describes… | Best first association | Reason |
|---|---|---|
| Oxidized, deaminated or alkylated single base | BER | A glycosylase removes a damaged base; a short patch is restored. |
| UV-induced pyrimidine dimer or bulky adduct | NER | A lesion-containing oligonucleotide is excised and replaced. |
| Replication mismatch or small insertion/deletion loop | MMR | Post-replication correction limits microsatellite errors. |
| Double-strand break with sister chromatid available | HR | Uses a homologous template, commonly in S/G2. |
| Double-strand break needing rapid end-joining | NHEJ | Joins DNA ends without a sister-chromatid template. |
| Crosslink joining both DNA strands | Fanconi pathway / coordinated crosslink repair | Unhooking and repair must be coordinated with replication and HR. |
- Do not say DNA polymerase synthesizes DNA 3′→5′; it adds to the 3′ end, so new DNA grows 5′→3′.
- Do not confuse proofreading (during synthesis) with MMR (after synthesis).
- Do not assign thymine dimers to BER; bulky UV lesions are the classic NER clue.
- Do not assume every MMR-deficient tumour is inherited Lynch syndrome.
- Do not describe all double-strand break repair as error-free; NHEJ can introduce small sequence changes.
- Do not call photoreactivation the human mechanism for UV repair; humans rely on NER.
- Do not interpret a BRCA finding as an automatic drug prescription; clinical eligibility is specific.
16. Self-test: multiple-choice questions
- DNA polymerase extends a new strand by adding a nucleotide to which group?
- 5′ phosphate on the growing strand
- 3′ hydroxyl on the growing strand
- 2′ hydroxyl on the template
- Any end of the DNA molecule
Answer: B. Addition to the 3′-OH means synthesis proceeds 5′→3′.
- Why are Okazaki fragments produced?
- DNA ligase works only on the leading strand
- The parental DNA is not antiparallel
- DNA synthesis is restricted to 5′→3′ on antiparallel templates
- Helicase moves in the wrong direction
Answer: C. The lagging template must be copied discontinuously as the fork opens.
- A UV photoproduct creates a bulky distortion in DNA. Which pathway is the classic response?
- Mismatch repair
- Nucleotide-excision repair
- Homologous recombination only
- Telomerase
Answer: B. NER removes a short DNA segment containing bulky helix-distorting damage.
- Which pathway chiefly corrects a replication mismatch that escaped polymerase proofreading?
- MMR
- NER
- Telomere extension
- Transcription-coupled translation
Answer: A. Mismatch repair acts after the error escapes the replication fork.
- A tumour is MSI-high with loss of an MMR protein. Which interpretation is most accurate?
- Lynch syndrome is proven in every case
- MMR deficiency is suggested; inherited versus somatic cause needs assessment
- NER is definitely defective
- The tumour cannot respond to any treatment
Answer: B. Tumour testing identifies a repair phenotype but does not by itself establish an inherited variant.
- Which repair pathway uses a sister chromatid as a template for a double-strand break?
- HR
- NER
- BER
- Direct reversal
Answer: A. Homologous recombination can use the sister chromatid and is favoured when it is available in S/G2.
- What is a key role of telomerase?
- Removing RNA primers from all Okazaki fragments
- Extending telomeric DNA using its internal RNA template
- Repairing all UV damage
- Joining DNA double-strand breaks by NHEJ
Answer: B. Telomerase helps maintain chromosome ends in cells where it is active.
- Which sensor is classically associated with replication stress and persistent single-stranded DNA?
- ATR
- Photolyase
- DNA ligase I
- Telomerase
Answer: A. ATR signalling is strongly linked to stalled forks and replication stress.
17. Short-answer revision prompts
- Draw and label a replication fork. Include helicase, RPA/SSB, primase, leading strand, lagging strand, Okazaki fragments and ligase.
- Compare BER, NER and MMR by the lesion each recognizes and the size of DNA removed.
- Explain why a tumour MSI/IHC result and a germline genetic result are not interchangeable.
- Outline how HR deficiency can create sensitivity to PARP inhibition, and state why that mechanism alone is not a prescribing decision.
18. Key take-home points
- Replication is semi-conservative and occurs in a tightly controlled cell-cycle window.
- Polymerases extend only 5′→3′; this creates continuous leading and discontinuous lagging strand synthesis.
- Fidelity depends on nucleotide selection, proofreading and mismatch repair.
- Match the lesion before naming the pathway: small base lesion—BER; bulky distortion—NER; replication mismatch—MMR; double-strand break—HR or NHEJ; interstrand crosslink—Fanconi-associated coordination.
- NER failure is classically associated with XP; MMR failure with Lynch syndrome; HR defects including BRCA1/2 can have treatment implications in selected cancers.
- Tumour screening results can suggest a pathway defect but do not automatically establish a germline diagnosis.
References and further study
- Alberts B, et al. Molecular Biology of the Cell. Chapter: DNA Replication, Repair, and Recombination. NCBI Bookshelf. Read the NCBI chapter.
- Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environmental and Molecular Mutagenesis. 2017. Full text at PubMed Central.
- Iyama T, Wilson DM III. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair. 2013. Full text at PubMed Central.
- GeneReviews. Lynch Syndrome. NCBI Bookshelf. Clinical and genetic overview.
- GeneReviews. Xeroderma Pigmentosum. NCBI Bookshelf. Clinical and molecular overview.
- National Cancer Institute. Olaparib. Drug and DNA-repair mechanism.
Supplemental lecture slides
DNA Replication and Repair — SlideShare lecture by Nirajan Shrestha. This is an optional visual study aid for replication, proofreading and excision-repair concepts. Slide decks can simplify or date details; use the NCBI, GeneReviews and peer-reviewed references above for pathway interpretation and current clinical context.
Educational revision material only. It is not a substitute for current clinical guidelines, specialist advice or individualized genetic counselling.
